EP0583142

A complete, commercial scale highly reproducible process for producing stable hepatitis A virus (HAV) comprises optimized growth, harvest, and antigen purification conditions, to yield a >95% pure HAV on the basis of protein. Further processing steps yield an inactivated HAV vaccine formulation w...

Full description

Saved in:
Bibliographic Details
Main Authors JUNKER, BETH, DEPHILLIPS, PETER A, HENNESSEY JR., JOHN P, LEWIS, JOHN A, BUCKLAND, BARRY C, ORELLA, CHARLES J, ABOUD, ROBERT A, HAGEN, ANNA J, AUNINS, JOHN G, OLIVER, CYNTHIA NEWELL, SITRIN, ROBERT D
Format Patent
LanguageEnglish
Published 13.04.1994
Edition5
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:A complete, commercial scale highly reproducible process for producing stable hepatitis A virus (HAV) comprises optimized growth, harvest, and antigen purification conditions, to yield a >95% pure HAV on the basis of protein. Further processing steps yield an inactivated HAV vaccine formulation which is immunogenic, well tolerated, and efficacious in protection against infection by virulent HAV. The product content of protein, carbohydrate, lipid, DNA and RNA is characterized.
Bibliography:Application Number: EP19930306223